Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma
The Journal of Infectious Diseases · 15.09.2025 · 232 (3) · e518-e528
DOI: 10.1093/infdis/jiaf279 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 28.05.2025. Verfasst von Wan-Yu Chu und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Antifungal Agents, Itraconazole, Mycetoma, Triazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Global Health Innovative, Technology Fund, Dutch Ministry of Foreign Affairs, Swiss Agency for Development and Cooperation.
Abstract (Originalsprache)
Background
The first clinical trial on eumycetoma was recently conducted in Sudan, comparing oral fosravuconazole, prodrug of active ravuconazole, with the standard-of-care oral itraconazole. Building on this trial, the present study aimed to characterize the pharmacokinetics-pharmacodynamics (PK-PD) of ravuconazole, itraconazole, and hydroxyitraconazole in patients with eumycetoma and guide selection of either a 200-mg or 300-mg dose of fosravuconazole.
Methods
Nonlinear mixed-effects modeling was used to develop population PK models in 52 patients receiving 3 daily loading doses followed by weekly fosravuconazole (200 mg or 300 mg) or twice-daily itraconazole (total 400 mg), both over 12 months. Attainment of the in vitro 90% minimum inhibitory concentration (MIC90) for Madurella mycetomatis was assessed, and the relationships between drug exposure, lesion size reduction, and complete cure were evaluated.
Results
Ravuconazole PK followed a 2-compartment model with Michaelis-Menten elimination and a 63% (95% confidence interval, 38%–90%) bioavailability increase during the loading phase, leading to 75% higher exposure for a 50% dose increase. Itraconazole and hydroxyitraconazole were modeled jointly, with autoinhibition of itraconazole metabolism. Free ravuconazole remained above the MIC90 throughout the entire 12-month treatment period, while free itraconazole never reached the MIC90. Despite a large range in antifungal exposure, no significant relationships were found between drug exposure and lesion size reduction or complete cure, indicating no additional benefit of 300 mg over 200 mg fosravuconazole.
Conclusions
Ravuconazole and itraconazole showed nonlinear clearance with no clear exposure-response relationship. The 200 mg fosravuconazole dose is preferred for future use over 300 mg, as it lowers pill burden and enhances cost-effectiveness. Clinical Trials Registration. NCT03086226.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Mycetoma Research Center, University of Khartoum, Khartoum, Sudan.
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
- Drugs for Neglected Diseases Initiative, Nairobi, Kenya.
- Department of Pharmacy, Radboud University Medical Center-Canisius Wilhelmina Ziekenhuis (Radboudumc-CWZ Center) Expertise for Mycology and Radboudumc Institute for Medical Innovation, Radboud University Medical Center,…
ORCID-Profile: Wan-Yu Chu, Sahar Mubarak Bakhiet, Osama Elhadi Bakhiet, Borna A Nyaoke, Thomas P C Dorlo
Förderung
- Global Health Innovative, Technology Fund
- Dutch Ministry of Foreign Affairs
- Swiss Agency for Development and Cooperation
- Republic and Canton of Geneva, International Solidarity Service
- Médecins Sans Frontières International
- Médecins Sans Frontières Switzerland
- UK International Development
- Swedish Research Council
Zitieren
APA
Chu, W. Y., Fahal, A. H., Ahmed, E. S., Bakhiet, S. M., Bakhiet, O. E., Fahal, L. A., Mohamed, A. A., Mohamedelamin, E. S. W., Bahar, M. E. N., Attalla, H. Y., Siddig, E. E., Mhmoud, N. A., Musa, A. M., Oyieko, P., Egondi, T., Brüggemann, R. J., Hata, K., Strub-Wourgaft, N., Alves, F., …, & Dorlo, T. P. C. (2025). Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma. The Journal of Infectious Diseases, 232(3), e518-e528. https://doi.org/10.1093/infdis/jiaf279
Vancouver
Chu WY, Fahal AH, Ahmed ES, Bakhiet SM, Bakhiet OE, Fahal LA, et al. Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma. The Journal of Infectious Diseases. 2025;232(3):e518-e528. doi:10.1093/infdis/jiaf279
BibTeX
@article{Chu2025,
author = {Chu, Wan-Yu and Fahal, Ahmed H and Ahmed, Eiman Siddig and Bakhiet, Sahar Mubarak and Bakhiet, Osama Elhadi and Fahal, Lamis Ahmed and Mohamed, Abubakar Ahmed and Mohamedelamin, El Sammani Wadaa and Bahar, Mustafa El Nour and Attalla, Hadil Yassir and Siddig, Emmanuel Edwar and Mhmoud, Najwa A and Musa, Ahmed Mudawi and Oyieko, Peelen and Egondi, Thaddaeus and Brüggemann, Roger J and Hata, Katsura and Strub-Wourgaft, Nathalie and Alves, Fabiana and Nyaoke, Borna A and Zijlstra, Eduard E and Dorlo, Thomas P C},
title = {Pharmacokinetics and Pharmacodynamics of Fosravuconazole, Itraconazole, and Hydroxyitraconazole in Sudanese Patients With Eumycetoma},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {3},
pages = {e518--e528},
doi = {10.1093/infdis/jiaf279}
}
EUVIMED